N-Acetyl Semax Amidate: Discovery and Research History

Introduction

N-Acetyl Semax Amidate (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂) is a synthetic heptapeptide that represents a structural refinement of Semax, itself an analog of the ACTH(4–10) fragment. Understanding the history of N-Acetyl Semax Amidate requires tracing the longer scientific lineage of ACTH fragment research — beginning in mid-twentieth century endocrinology, passing through Soviet and Russian academic neuropharmacology during the 1980s and 1990s, and extending into ongoing structural pharmacology investigations that continue into the 2020s. The fully amidated variant did not arise from a single discovery event but from the cumulative structure-activity research surrounding its parent peptide [1]. A parallel neuropeptide research tradition from the same era produced Selank, a compound with a distinct tuftsin-based scaffold whose development also proceeded through Soviet academic pharmacology before achieving Russian regulatory recognition.

Discovery Period: ACTH Fragment Science (1950s–1970s)

Adrenocorticotropic hormone (ACTH) is a 39-amino acid peptide produced in the anterior pituitary that stimulates cortisol secretion from the adrenal cortex. In the 1950s and 1960s, pharmacologists observed that fragments of the ACTH sequence retained distinct behavioral and neurotrophic properties dissociable from the steroidogenic activity carried by residues 1–24. The fragment ACTH(4–10) — carrying the sequence Met-Glu-His-Phe-Pro-Gly-Pro — was identified through systematic truncation studies as a minimal active sequence capable of influencing animal learning and memory consolidation without activating the adrenal steroidogenic pathway [1].

This observation prompted substantial interest in ACTH-derived peptides as research tools for studying cognitive neuroscience and as candidate pharmacological agents. The ACTH(4–10) sequence subsequently formed the common structural scaffold for a family of synthetic melanocortin analogs developed across several research programs in Europe, the United States, and the Soviet Union through the 1970s and 1980s.

Early Research: Soviet-Era Development of Semax (1980s)

The direct antecedent of N-Acetyl Semax Amidate was developed in the Soviet Union beginning in the early 1980s. Research groups led by Nikolai F. Myasoedov at the Institute of Molecular Genetics of the Soviet (later Russian) Academy of Sciences and by Igor P. Ashmarin at Moscow State University undertook systematic synthetic chemistry work aimed at extending the biological activity duration of ACTH(4–10) analogs. The underlying hypothesis was that appending a C-terminal tripeptide extension — Pro-Gly-Pro — to the ACTH(4–10) sequence would slow enzymatic degradation and prolong central nervous system activity [1].

This research produced Semax (Met-Glu-His-Phe-Pro-Gly-Pro), the heptapeptide whose sequence incorporates the ACTH(4–10) core together with the appended Pro-Gly-Pro tripeptide at the C-terminus. Systematic behavioral pharmacology work in rodent models during the 1980s characterized the compound's effects in learning and memory paradigms, laying the empirical foundation for its subsequent clinical investigation. The Ashmarin and Myasoedov groups published a historical account in the late 1990s describing approximately 15 years of design and study work on the compound [1].

Koroleva and Myasoedov (2018) later reviewed the Semax research program in Biology Bulletin, summarizing pharmacological characterization from the 1980s through the 2010s across multiple experimental and clinical domains — one of the most comprehensive English-language accounts of this research lineage [1].

Regulatory Milestones

Semax received approval from the Russian Ministry of Health in 1994 for specific cerebrovascular indications, representing one of the few peptides from the Soviet-era neuropharmacology program to achieve full national regulatory registration. The approved formulation was a nasal spray containing the unmodified heptapeptide sequence (Met-Glu-His-Phe-Pro-Gly-Pro). The compound entered Russian neurological clinical settings, primarily for ischemic stroke and related conditions, under this registered approval — a regulatory achievement that distinguished Semax from most synthetic neuropeptide analogs of its generation [1].

Outside Russia, neither Semax nor its terminal-modified derivatives have received regulatory approval. In the United States, the FDA categorized Semax (free base and acetate forms) under the Section 503A bulk drug substances framework — a pathway governing compounding pharmacy use of non-approved substances — as Category 2, pending further review. The FDA's Pharmacy Compounding Advisory Committee (PCAC) was scheduled to review Semax's candidacy for the 503A Bulk Drug Substances List at a meeting on July 24, 2026. The N-acetyl amidate variant is not separately named in that proceeding, and N-Acetyl Semax Amidate is sold in the United States as a research-use-only material [2].

Structural Modification Studies and the Emergence of N-Acetyl Semax Amidate

Following the establishment of Semax's preclinical and clinical research base, subsequent investigators explored systematic structural modifications designed to probe the determinants of biological activity and metabolic stability. Two parallel lines of work are relevant to N-Acetyl Semax Amidate:

N-terminal modification studies: Levitskaya, Sebentsova, Andreeva, Myasoedov and colleagues (2005) conducted a systematic comparison of Semax analogs bearing varied N-terminal amino acid residues or N-terminal acyl modifications in rat behavioral learning models. They reported that N-terminal acetylation of methionine was among the modifications compatible with retention of the peptide's behavioral activity profile in the tested models, while substitution with certain non-polar amino acids abolished measurable activity — directly establishing the pharmacological permissibility of N-terminal acylation in this peptide class [3].

Degradation studies by Shevchenko and colleagues (2006) — using intranasal radiolabeled Semax in rats — characterized brain penetration kinetics, reporting that intact Semax was detectable in rat brain tissue within two minutes of intranasal administration, though a substantial fraction was already present as metabolic fragments. The C-terminal Pro-Gly-Pro tripeptide accumulated as a primary early metabolite, providing the rationale for dual terminal protection to extend the intact peptide's presence in target tissue [4].

Coordination chemistry studies with N-acetyl Semax: The 2016 study by Magrì and colleagues, published in the Journal of Inorganic Biochemistry, represents direct published research on the N-terminally acetylated variant of Semax. Motivated by interest in how the free N-terminal amine participates in copper(II) and zinc(II) coordination, the investigators synthesized N-acetyl Semax to dissect this question. They found that the modified peptide forms a geometrically distinct copper complex and that the copper-dependent cytoprotective activity observed with the free-amine form in neuroblastoma cell experiments depends specifically on the intact terminal amine. This work established how N-terminal modification selectively alters one pharmacological activity while leaving others open for characterization [5].

C-terminal amidation — the modification that distinguishes the amidate form used in research preparations — is a chemical modification employed by peptide chemists to confer resistance to carboxypeptidase activity and to mimic the structure of endogenously amidated neuropeptides. Combined with N-terminal acetylation, it constitutes a well-characterized dual-protection strategy applied across synthetic neuropeptide chemistry.

Current Research Landscape

The most active threads of published Semax research through the 2020s have expanded from the foundational behavioral pharmacology and ischemia models into proteomics, calcium signaling, and neurodegenerative disease models. Sudarkina, Filippenkov and colleagues (2021) employed proteomics to characterize Semax-associated protein changes in rat ischemia-reperfusion models, identifying over 40 proteins significantly associated with peptide exposure [6]. A 2025 publication from Korolev and colleagues in the Bulletin of Experimental Biology and Medicine characterized Semax effects on spontaneous calcium oscillations in hippocampal CA1 pyramidal cells, representing a mechanistic research direction distinct from the gene-expression focus of earlier work [7]. Radchenko and colleagues (2025) examined Semax and a derivative compound in a transgenic mouse model of Alzheimer's pathology, extending the scope of Semax-family research beyond vascular ischemia into neurodegenerative model systems — a significant extension of the original research program's scope [8].

Structural pharmacology characterization of the fully amidated variant, including head-to-head comparison between Semax, N-acetyl Semax, and N-Acetyl Semax Amidate in matched experimental systems, represents one of the methodologically tractable next steps for this research area. The July 2026 PCAC meeting on Semax's 503A candidacy may generate regulatory documents that address the analytical characterization and research status of Semax-family peptides more comprehensively; those documents, if published, would represent a significant primary source addition to the regulatory history of this compound class [2]. Research-grade N-Acetyl Semax Amidate from SpartaLabs is available with batch-specific certificates of analysis for research use.

References

1. Koroleva SV, Myasoedov NF. Semax as a universal drug for therapy and research. Biol Bull. 2018;45(6):589–600. DOI: 10.1134/S1062359018060055

2. US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory committee calendar. Available at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

3. Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, Kamenskiy AA, Myasoedov NF. Effect of modification of the N-terminal region of Semax on the expression of nootropic effect of Semax analogs. Biol Bull. 2005;32(4):381–386. DOI: 10.1007/s10525-005-0116-0

4. Shevchenko KV, Nagaev IY, Alfeeva LY, Andreeva LA, Kamenskii AA, Levitskaia NG, et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Russ J Bioorg Chem. 2006;32(1):57–62. DOI: 10.1134/S1068162006010055

5. Magrì A, Munzone A, Peana M, Medici S, Zoroddu MA, Hansson Ö, et al. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem. 2016;164:59–69. PMID: 27586814. DOI: 10.1016/j.jinorgbio.2016.08.013

6. Sudarkina OY, Filippenkov IB, Stavchansky VV, Denisova AE, Gubsky LV, Limborska SA, et al. Brain protein expression profile confirms the protective effect of the ACTH(4–7)PGP peptide (Semax) in a rat model of cerebral ischemia–reperfusion. Int J Mol Sci. 2021;22(12):6179. PMID: 34201112. DOI: 10.3390/ijms22126179

7. Korolev DO, Zolotarev YA, Grivennikov IA. The effect of peptide Semax, an ACTH(4-10) analogue, on intracellular calcium dynamics in rat brain neurons. Bull Exp Biol Med. 2025. DOI: 10.1007/s10517-025-06501-z

8. Radchenko EV, Palyulin VA, Zefirov NS. The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer's disease. Acta Naturae. 2025;17(4):110–120. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12755871/